Akeso, Inc. Is an investment company, which engages in the research and development, production, and sale of biopharmaceuticals products. The company is headquartered in Zhongshan, Guangdong and currently employs 3,529 full-time employees. The company went IPO on 2020-04-24. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The firm's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.
09926.HK stock price ended at $105.3 on viernes, after rising 1.54%
On the latest trading day Feb 13, 2026, the stock price of 09926.HK rose by 1.54%, climbing from $102.20 to $105.30. Throughout the session, the stock experienced a volatility of 3.43%, with prices fluctuating between a daily low of $102.10 and a high of $105.60. Alongside this price increase, trading volume also rose by 129.5K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 2.9M shares were traded, amounting to a market value of approximately $96.9B.
Señales Técnicas de 09926.HK
Resumen de Señales Técnicas
Señales de compra 1
Señales Neutras 2
Señales de venta 4
Strong Sell
Sell
Neutral
Buy
Strong Buy
09926.HK actualmente presenta 1 señales de compra y 4 señales de venta. La acción ha estado en una tendencia alcista desde 12:00 AM, con un cambio total en el precio de 1.54% durante este período. En general, los indicadores técnicos apuntan a una perspectiva Sell para el mediano plazo.
Señales alcistas/bajistas para 09926.HK
Analizamos indicadores clave como medias móviles, RSI, MACD y volumen de negociación para generar señales alcistas y bajistas para 09926.HK. Estas perspectivas te ayudan a tomar decisiones de inversión más informadas.